Non-covalent AFP-complexes attract a great interest due to their targeting ability to selectively induce apoptosis in the tumor cells using AFP-receptor  mediated mechanism of endocytosis. An anticancer “magic bullet” should have both

efficacy and specificity parts. We have used an effective apoptosis inducer to trigger the apoptosis. Alpha-fetoprotein was

used to deliver apoptosis inducers specifically to cancer cells.  The drug delivery system based on native AFP, which as

shown, can bring agent inside the tumor cell via receptor-mediated endocytosis.  


We evaluated in vivo the efficacy and the pharmacokinetic of the new oral atractyloside porcine AFP complex - AIMPILA. 

The efficacy was studied using oral daily doses 0,1–0,4 mg/kg for 5-10 days on s.c. human tumor xenografts featuring different expression of AR: SW620/AR+, HepG2/AR++ 
and T47D/AR+++. Also, we studied AMP’s efficacy using corresponding doses in rabbit (VX2, AR+) tumors in

acid resistant capsules & the murine(P388) tumor (oral or intravenius). 

Biodistribution of radioactive iodine labeled  Aimpila and AFP in the tumor, stomach and blood compared to normal mammary gland was studied using a direct radiometry within 24 h following oral drug administration. The radioactivity was measured using gamma counter.
We founded that AMP caused a significant tumor growth inhibition in vivo depending of AFP expression in the tumors studied: T47D (Тreated/Сontrol = 22%) > HepG2 (Т/С = 51%) > SW620 (T/C = 70%) (model criterion T/C should be lower than 42%). The effect of Aimpila for non-human tumor models didn’t match the criterion. 

Studing the biodistribution and pharmacokinetiс the tumor accumulation showed peak time of llabeled Aimpila  was 6 times longer than AFP (3 versus 0.5 hours). The maximum concentration of iodine labeled Aimpla in the tumor was

accumulated faster than in the mammary gland  of the Balb/c nude+ mice with a peak time of 3h for T47D versus 6 hors for the control mammary gland. Maximum tumor/blood ratio was at 1 h for Iodine labeled Aimpila versus 6 hours for iodine

AFP (0.86 and 0.83, respectively). After 6 hours both showed similar level of accumulation and the elimination rate in the

tumor. The retention period was longer for the tumor as well (MRT = 12.3 h vs 9.5 h). By 24 h time period the radioactivity

amount Aimpila in the tumor was 5 times higher than in the mammary  gland (ID/g = 0.87±0.08% versus ID/g = 0.18±0.09%, respectively with p = 0.002). 

We can state thet high efficacy of low doses orally administrated AMP was achieved due to the AR targeting, receptor-

mediated binding resulting in long retention of AMP in T47D. Oral administration of AMP showed intestinal absorption and



The OncoShuttle™ technology was developed by Constab Pharmaceutical Inc., Toronto. Fast-Diag uses the technology

and trademark according local license.